Venus Medtech targets European opportunities

Venus Medtech, which provides solutions for structural heart disease in China, has appointed Shakeel Osman as senior vice president of sales Europe, responsible for the commercialisation of congenital heart devices.

At present, the company’s transcatheter pulmonic valve replacement (TPVR) system VenusP-Valve designed for congenital heart disease patients is awaiting CE mark approval.

Prior to joining Venus Medtech, Shakeel Osman served as general manager UK and vice president sales Middle East Asia and Africa at Occlutech Medical Devices, a Germany-based global leading provider of minimally invasive cardiac devices.

As a 20-year veteran in the global marketing of medical devices, Osman has been heavily engaged in the European and Middle East markets, boasting extensive experience in marketing and distributor management in the cardiovascular field.

He Osman said, “It is a great honor to join Venus Medtech‘s commercialisation team in Europe. As a leading company in structural heart disease, Venus Medtech possesses internationally competitive innovative pipelines. I’m excited to leverage my experience and work closely with the team to lay a solid foundation for the commercialization of VenusP-Valve across Europe and contribute to the company’s global presence.”

VenusP-Valve is the only self-expanding TPVR system undergoing CE certification at the present time.

It is expected to be Venus Medtech’s second medical device marketed in Europe following TriGUARD3™ cerebral embolic protection device.

In March 2021, VenusP-Valve received a special use authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Venus also recently appointed David Breant as vice president of sales Europe, and Joyce Heo as director of sales, responsible for sales in emerging markets.